Loss of heterozygosity (LOH) represents the most frequent genetic alteration observed in hepatocellular carcinoma (HCC). Chromosome 16q is of particular interest as it exhibits LOH in 29% of HCC tumors and is frequently lost in breast, prostate, ovarian and gastric carcinomas. We genotyped 157 HCC tumors for 17 microsatellite markers distributed on chromosome 16q and determined a common region of LOH localized between the markers D16S518 and D16S504. By re®ning the boundaries of two interstitial LOH and two homozygous deletions, the critical region was delimited to 180 kb between D16S3096 and D16S3029. This region is located in intron 8 of the WWOX/FOR gene, but a search for mutations in all coding exons of this gene in 27 HCC tumors and cell lines did not reveal any tumor somatic alterations. Furthermore, by RT ± PCR, no abnormal transcripts of this WWOX/FOR gene was detected in nine HCC cell lines. Finally, analysis of the p53 gene mutations with the clinical parameters of all tumors revealed that the two homozygous deletions have occurred in tumors presenting a R249S mutation. Our data revealed a relationship between chromosome 16q homozygous deletions and R249S p53 mutations in tumors where the patient had been exposed to A¯atoxin B1 (P=0.002). These results are consistent with a role of A¯atoxin B1 in the instability of chromosome 16q at the fragile site FRA16D. However, the nature of the speci®c gene that is altered during hepatocarcinogenesis remains to be elucidated. Oncogene (2001) 20, 5232 ± 5238.
Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors in Africa and Asia. In developed countries, HCC incidence is lower (approximately 2/100 000), but the increase in the number of new patients re¯ects the strong impact of environmental factors on the pathogenesis of these tumors (ElSerag and Mason, 1999) . HCC risk factors are well characterized; infection by hepatitis B (VHB) and C (VHC) viruses, cirrhosis of any etiology, primitive hemochromatosis and prolonged exposure to A¯atoxin B1 have all been documented (Tsukuma et al., 1993) . Although, mechanisms of carcinogenesis are not fully elucidated, they seem to be dierent according to the risk factor implicated (Laurent-Puig et al., 2001; Marchio et al., 2000; Wong et al., 2000) .
Dierent genetic alterations in HCC have been identi®ed in each category (for review see Buendia (2000) ; Feo et al. (2000) ). Speci®c mutation of the p53 gene at codon 249 was found in 50% of HCCs in Asian and African populations that had been exposed to A¯atoxin B1 (Bressac et al., 1991; Hsu et al., 1991) . In the non-exposed populations, the prevalence of the p53 gene mutation is lower (20%) and codon 249 is only exceptionally altered (Buetow et al., 1992; Oda et al., 1992) . More recently, speci®c mutation of exon 3 of the b-catenin gene and inactivating mutations of the Axin gene that activated the Wnt/wingless carcinogenesis pathway were observed in approximately 25 ± 30% of the cases (de La Coste et al., 1998; Laurent-Puig et al., 2001; Legoix et al., 1999; Miyoshi et al., 1998; Satoh et al., 2000) . Finally, a variety of gene alterations have been described in less than 10% of the HCC cases, i.e. RB1, K-ras, N-ras, H-ras, p16, IGF2R, SMAD2 and SMAD4 mutations (for review see Buendia (2000) ; Feo et al. (2000) ; Ozturk (1999) ).
Allelotype studies have revealed multiple loss of heterozygosity (LOH) on dierent chromosomal arms representing the most frequent genetic alterations observed in HCC. Cytogenetic studies, and more recently comparative genomic hybridization (CGH) as well as high density allelotyping has shown recurrent allelic losses on chromosomes 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 17p (Boige et al., 1997; Marchio et al., 1997; Nagai et al., 1997; Okabe et al., 2000) . Chromosome 16q LOH has been observed in about 30 ± 40% of the cases, in dierent studies. The critical region of LOH on chromosome 16q is not clearly de®ned since at least three dierent candidate regions have been successively proposed in 16q21, 16q22 and 16q24 by dierent allelotype analyses (Bando et al., 2000; Chou et al., 1998; Piao et al., 1999) . Furthermore, the chromosome 16q LOH is of particular interest in cancer genetics because of its frequent loss in many other types of tumor including prostate, breast and ovarian cancers (Chen et al., 1996; Driouch et al., 1997; Iwabuchi et al., 1995; Latil et al., 1997) . The tumor suppressor gene presumed to be located on this chromosome arm is not known. In order to localize the putative tumor suppressor gene implicated in liver carcinogenesis, we searched for LOH and homozygous deletion on the long arm of chromosome 16q in a series of 157 HCC tumors.
Results and discussion

LOH status assessment on chromosome 16q
A set of 157 HCC tumors was screened for LOH using a panel of 17 microsatellite markers distributed on chromosome 16q. Allelic losses were identi®ed when at a heterozygous locus the intensity of one allele in the tumor was decreased by at least a factor 2 when compared to the intensity in the matching non-tumor DNA and after normalization on the second allele intensity . In 45 of 157 cases of HCC (29%), at least one of the chromosome 16q markers showed LOH. In 39 cases all the informative loci exhibited LOH demonstrating the deletion of the entire chromosome 16q arm. In contrast, deletion of 16q was partial in two cases (CHC040 and CHCC050), encompassing the telomeric part of the chromosome. In two additional cases, CHC162 and CHC092, the deletion was interstitial (Figure 1 ). Data collected from these 43 heterozygous deletions pointed to a common region of deletion located within a 6 cM interval, bounded by D16S518 and D16S504. This region corresponds to that de®ned by homozygous deletions recently reported in ovarian, gastric, colon and small cell lung carcinoma cell lines (Bednarek et al., 2000; Paige et al., 2000; Ried et al., 2000) . Furthermore, the chromosome 16q breakpoint of t(14;16)(q32.3;q23) translocations in myeloma have been also mapped to this same region (Chesi et al., 1998; Krummel et al., 2000) .
In the remaining two cases of HCC (CHC014 and CHC016), all the informative loci analysed on 16q exhibited a LOH with the exception of D16S3049 and D16S3096 where a heterozygous pro®le was observed in the tumor DNA with an allele ratio intensity perfectly matching the non-tumor DNA. The genotyping results were con®rmed by re-ampli®cation of the two loci with external primers as described in Bluteau et al. (1999) . These results suggested a deletion of the entire chromosome arm with an additional interstitial deletion located in the D16S3049 ± D16S3096 region of the remaining arm in these two tumors. The retention of heterozygosity that was observed in these two tumors could be explained by the ampli®cation of both alleles from normal DNA contaminating the tumor sample.
Fine deletion mapping
To re®ne the deletion mapping we constructed a physical map of the region D16S518 ± D16S504 by screening a BAC library with all STS and polymorphic markers previously mapped in this region ( Figure 2a ). The extremity of each BAC was sequenced and STSs and polymorphic markers were ordered. New markers, polymorphic or not, were identi®ed in this region (Table 1 and Figure 2a ). Using this information, the extent of the region of LOH in cases CHC162 and CHC092 was estimated to be less than 600 and 800 kb, respectively ( Figure 2a ). These two tumors de®ne a 300 kb minimal common region of deletion from the AFCA marker (Table 1) to D16S504.
To identify and characterize the putative homozygous deletion in tumors CHC014 and CHC016, hyperploid tumor nuclei were puri®ed by¯ow cytometric sorting based on the nuclear DNA content. DNA extracted from 100 000 puri®ed nuclei were subjected to a multiplex PCR. In this procedure control markers, CHR22 or D4S1558 (Table 1) , were chosen on chromosome 22 or 4, respectively, to coamplify with the tested locus on chromosome 16q. The larger size of the so control PCR fragment ensures that a failure to amplify the tested locus is not due to unwanted DNA degradation ( Figure 2b ). This method allowed a clear identi®cation of the two homozygous deletions in the D16S518 ± D16S504 region. deleted region bounded by markers AFCA and EXT419 (Figure 2a ). These two loci delimit a 180 kb critical region of deletion located in intron 8 of the WWOX/ FOR gene recently described (Figure 2a , Bednarek et al., 2000; Ried et al., 2000) . However, there was no overlap between the more proximal homozygous deletions described in the colon and gastric carcinoma cell lines HCT116 and AGS (Ried et al., 2000) and the two HCC homozygous deletions (Figure 2a ).
WWOX/FOR gene mutation screening
The WWOX/FOR gene encoded a protein that contains two WW domains coupled to a region presenting a high homology to the short-chain dehydrogenase/reductase (SRD) family of enzymes (Bednarek et al., 2000) . This gene covers a genomic region larger than 800 kb from the D16S518 to the D16S504 markers located near the ®rst exon and the ninth exon, respectively (Figure 2a) . Four dierent alternatively spliced WWOX/FOR transcripts have been identi®ed by Ried et al. (2000) . In order to document possible alterations of the WWOX/FOR gene in HCC, 17 tumors demonstrating LOH in the 16q23 region and nine cell lines were selected. For each tumor and cell line, the entire coding sequences of WWOX/FOR gene was ampli®ed from genomic DNA. PCR products were then sequenced directly. Two previously described frequent polymorphisms were observed, one ®ve bases before the start codon and one at base number 535 in 12 and 10 cases, respectively (Table 2 ). Six new rare gene alterations leading an amino acid substitution were identi®ed within exon 4 to 8 in one or two tumors in each case, but were also observed in all corresponding nontumor DNA (Table 2 ). These amino-acid substitutions were interpreted as polymorphisms since they were not of somatic origin and that they did not alter conserved amino acids in the ADH domain of WWOX/FOR. Apart from these polymorphisms, none of the 27 tumor DNAs studied revealed an alteration in the WWOX/FOR gene exons. Furthermore, RT ± PCR analysis on exon 1 to 9 performed on the nine RNA cell lines, 20 HCC tumors and 10 matching non-tumor tissues demonstrated neither abnormal WWOX/FOR transcript nor bases mutation after sequencing. Thus, in agreement with results observed in breast cancer (Bednarek et al., 2000) , no somatic alteration of the WWOX/FOR gene was observed in our HCCs. Furthermore, as described by Bednarek et al. (2000) and by Ried et al. (2000) , computational analysis of the DNA sequence of the critical region failed to identify a new gene.
Correlation with clinical characteristics
The relationship between chromosome 16q LOH status and the available clinical and histological parameters were also studied. A close association between 16q LOH and HBV infection was observed (P510
75
). In a previous study, mutation of the p53 gene were sought in all the 157 HCC tumors and were found in 26% of the cases (Laurent-Puig et al., 2001) . Among these mutated tumors, eight cases had the speci®c p53 mutation R249S. The two cases shown to have a chromosome 16q homozygous deletion (CHC014 and CHC016) belonged to this group suggesting a close association between chromosome 16q homozygous deletions and R249S (P=0.002 by Fisher exact test). It is interesting to note that these two patients were both born and lived in A¯atoxin exposed regions, i.e. Mauritania and Haiti, respectively (Autrup and Wakhisi, 1988; FAO/PAHO, 1991) suggesting that A¯atoxin B1 or the p53 R249S speci®c mutation is implicated in the occurrence of the homozygous deletions. A strong chromosome damaging eect of A¯atoxine B1 has been evidenced in various experimental assays including in vivo and in vitro conditions (Eckl et al., 1987; el-Zawahri et al., 1977; Fabry and Roberfroid, 1981; Preisler et al., 2000; Sengstag et al., 1996) . The main consequences of exposure to the A¯atoxin B1 were the increase in chromosome aberrations such as sister chromatid exchanges, single-strand DNA breaks and the formation of DNA adducts. A speci®c sensitivity of this 16q chromosomal region (FRA16D) to the action of A¯atoxin B1 can be evoked by the dierence in location of the homozygous deletions regions described here in hepatocellular carcinoma and those delimited previously in the colon HCT116 and the gastric AGS carcinoma cell lines (Ried et al., 2000) . As homozygous deletions are genetic events selected in HCC tumors, the alteration of a gene located in this chromosomal region and implicated in the hepatic carcinogenesis can be suggested. In the absence of somatic mutation and of abnormal expression of the WWOX/FOR gene, alterations of another gene remain to be found.
Materials and methods
Tumor and cell-line samples
Tumor samples from 157 HCC and matched non-tumor liver tissues were collected in four surgical treatment departments in France from 1992 to 1998. The samples were dissected and stored at 7808C until DNA extraction using the Qiaquick extraction kit (Qiagen, Hilden, Germany). All DNAs were quanti®ed using Hoechst 33258 (Sigma-Aldrich Inc.), bȳ uorometry on a Fluoroskan following the manufacturer's protocol (Thermo LabSystem, Issy-les-moulineaux, France) . Clinical data indicating the risk factor exposure, histological and Edmondson grading score were available for all patients. Seven HCC cell lines, i.e. SNU-182, SNU-387, SNU-398, SNU-423, SNU-449, SNU-475 and Hep 3B, were purchased from the American Type Culture Collection (Manassas, VA, USA) and cases PLC/PRF and HUH7 were kindly provided by Mehmet Ozturk (Bilkent University, Ankara, Turkey).
LOH analysis
A panel of 17 polymorphic microsatellite markers distributed on chromosome 16q was selected from the LMS2 panel (Perkin-Elmer) and from the Genethon database (Figure 1 ). PCR ampli®cations were performed using primers described in the Genethon database and following the ampli®cation procedure described in Bluteau et al. (1999) . Each forward primer was labeled with a 6-FAM, HEX or NED phosphoramidite (Oligo Express, Paris, France and Perkin Elmer, Corp.). Fluorescent PCR products were analysed on an Applied Biosystem 377 sequencer using the ABI Prism Genescan 2.1 software (Perkin Elmer, Foster City, CA, USA). The LOH status was de®ned by a quantitative analysis of the¯uorescent intensity of the two alleles in the normal compared to the tumor DNA performed with an automatic procedure developed in the laboratory using the Genotyper software (Perkin Elmer Corp.).
Sequencing procedure
A whole genome BAC library constructed in the`Centre d'Etude du Polymorphisme Humain' (CEPH, Paris, France) from a human lymphoblastoid cell line (individual 134702 from the CEPH families) in the pBELO BACII vector was screened by PCR for STS and microsatellite loci localized in the 16q23 region. To complete nucleotide draft sequences of chromosome 16 available in Genbank, shotgun sequencing of BAC DNA was performed as described in (Zucman-Rossi et al., 1996) with the exception of the use of a pUC19 vector (Fermentas, Vilnius, Lithuania) instead of M13. DNA extraction of 300 sub-clones per BAC was performed using the Qiagen REAL Prep 96 plasmid kit (Qiagen, Hilden, Germany) and sequenced with M13 universal and reverse primers using the Big dye terminator kit (Perkin Elmer Corp.). The 600 random sequences were assembled together with BAC draft sequences available in Genbank database using the PhredPhrap software package (University of Washington, Seattle, WA, USA).
Cytometry flow sorting
In two cases, hyperploid tumor nuclei were sorted on the basis of the DNA content essentially according to Boige et al. (1997) . Hoechst 33258 DNA staining nuclei were analysed and sorted using a Mo¯o MLS (Cytomation, Fort Collins, CO, USA) equipped with a coherent Innova 300-series argon- ion laser (Coherent, Santa Clara, CA, USA). For each tumor, 100 000 nuclei were sorted and DNA was extracted using the Qiaquick extraction kit (Qiagen, Hilden, Germany).
Mutation screening
Genomic DNA isolated from 17 HCC tumors exhibiting LOH of chromosome 16q and from nine HCC cell lines were PCR ampli®ed for all exons of the WWOX gene using the primers indicated in Table 1 . RT ± PCR of exon 1 to 9 of the WWOX gene was performed on RNA that had been extracted from the nine cell lines, 20 HCC tumors and 10 matched non-tumor tissues with the Trizol kit procedure (Life technologies, Rockville, MD, USA), using the GeneAmp RNA PCR Kit (Perkin Elmer Corp.) according to the manufacturer's instructions. PCR ampli®cations were performed using the primers described in Table 1 . All PCR products were sequenced using a PRISM Big dye terminator kit (Perkin Elmer Corp.) with PCR primers on both strands and analysed on an ABI 377 sequencer with the AutoAssembler software (Perkin Elmer Corp.).
